EU Pharmaceutical Regulations & Strategy Programme: Post-authorisation Strategy Discussion - Will Brexit Alter this? (London, United Kingdom, April 20-21, 2020)
This course will provide an up-to-date overview of the European pharmaceutical regulatory environment, procedures, and obligations. You will learn about the legal basis of regulation, development strategies and the strategic importance of pre-submission actions, the format for presentation of data, how the registration procedures work and post-authorisation strategies and obligations.
The programme will be of value to regulatory affairs personnel and also to those who interact with regulatory personnel in order to understand action timelines and information requirements.
Benefits of attending:
Understand the legal basis of the EU regulatory environment
Discuss development strategy and pre-submission activities
Review procedures for applying for an EU marketing authorisation
Discuss post-authorisation strategic considerations and obligations
Who Should Attend:
This course will be of particular relevance if you are involved in:
Regulatory affairs
Project management
Business planning
Commercial management
Manufacturing and QA
Labelling and artwork
Medical information
Clinical
Pharmacovigilance
Agenda:
Programme day one
Welcome and introduction
EU regulatory environment: legal basis
Key regulations, directives and guidelines and information sources
Impact of Brexit
Development strategy and pre-submission activities
Scientific advice
Pediatric use
Case study 1: Submission requirements
The Common Technical Document (CTD)
Structure and content of the CTD
The EMA
Impact of Brexit
Applying for marketing authorisation in the EU
Fast-track, conditional approval, and exceptional circumstances
Adaptive licensing
Centralised procedure (CP)
Case study 2: Registration strategy discussion
Will Brexit alter this?
Programme day two
Registration procedures
Co-ordination group
Decentralised procedure (DCP)
Mutual recognition procedure (MRP)
National procedures
Managing product labelling
Company core data sheets
Updates to SmPC
Abridged applications
Legal basis
Data exclusivity
Generics - definition, and criteria
Post-authorisation obligations and strategic considerations
Safety reporting
Pharmacovigilance
Licence variations
Type I and Type II variations
Strategic considerations
Line extensions
Classification switch
Parallel trade (impact of Brexit)
Phase IV studies
Case study 3: Post-authorisation strategy discussion
Sedana Medical AB (publ) announces that all 235 randomized patients have been recruited for its INSPiRE-ICU 1 phase III clinical trial in the United States. Concurrently, the identical INSPiRE-ICU 2 trial is nearing completion, with 23 of 235...
Quarter 1, 2024 - High profitability and strong cash flow
Net sales decreased 4.1% to SEK 34,850m (36,352)Organic growth amounted to -4.0%, of which volume accounted for -1.8% and price/mix -2.2%. Excluding restructuring and exited contracts, volumes...
ImmunityBio, Inc. , an immunotherapy company, today announced positive overall survival results in the QUILT 3.055 study of 2nd- and 3rd-line NSCLC patients who progressed after checkpoint inhibitor therapy (pembrolizumab, nivolumab, or atezolizumab)...
The Insurance Institute for Highway Safety is updating its vehicle-to-vehicle front crash prevention test to address crashes that occur at higher speeds and those in which the struck vehicle is a motorcycle or large truck. Only one of the first 10...
Nutriessential.com recently announced its expansion into Oceania, Asia, and the Gulf. The company has been providing science-backed GMP-certified supplements in the US, Europe and Canada since 2005 and decided to expand owing to rising global demands...
Summit Clinical Research LLC ("Summit") is deeply saddened by the death of Co-Founder and Chairman Dr. Stephen Harrison. Summit mourns Dr. Harrison and extends its heartfelt condolences to his family and loved ones.
During an illustrious 30-year...